Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rosuvastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | PDE6D | O43924 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.84 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.84 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.83 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.83 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.83 |
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.58 |
| ▸ | PDE4A | P27815 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rosuvastatin SCHEMBL28393539 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL32686257 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL41433 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL2520 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL3938301 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL154400 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL16995485 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL240433 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL8268193 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL29722976 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109580789-B | Method for separating and measuring rosuvastatin tert-butyl ester and optical isomer thereof by liquid chromatography | 安徽省庆云医药股份有限公司 | 2021-06-22 | — | — | CN | claimed |
| CN-111110854-A | Composition comprising a histamine release-promoting substance and an inhibitory compound | 黄泳华 | 2020-05-08 | — | — | CN | claimed |
| CN-111068064-A | Composition comprising fatty acid or derivative thereof and dihydroxyheptanoic acid derivative | 黄泳华 | 2020-04-28 | — | — | CN | claimed |
| CN-103585157-B | A kind of double-layer tablet containing Ezetimibe and Rosuvastatin and preparation method thereof | WUHAN WUYAO TECHNOLOGY CO., LTD. (CN) | 2016-02-03 | — | — | CN | claimed |
| EP-1539711-A1 | PROCESS FOR PREPARING THE CALCIUM SALT OF ROSUVASTATIN | AstraZeneca UK Limited (GB) | 2005-06-15 | — | — | EP | claimed |
| WO-2004014872-A1 | PROCESS FOR PREPARING THE CALCIUM SALT OF ROSUVASTATIN | ASTRAZENECA UK LIMITED (GB) | 2004-02-19 | — | — | WO | claimed |
| US-12622895-B2 | Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases | ALTO NEUROSCIENCE, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20240360086-A1 | ROSUVASTATIN CALCIUM AND PROCESS FOR PRODUCING INTERMEDIATE THEREOF | API CORPORATION (JP) | 2024-10-31 | — | — | US | disclosed |
| US-20230085863-A1 | TELOMERE LENGTH MODULATION USING FIBROBLASTS | FIGENE, LLC | 2023-03-23 | — | — | US | disclosed |
| EP-4106777-A1 | TELOMERE LENGTH MODULATION USING FIBROBLASTS | Figene, LLC (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20220370561-A1 | LITHIUM AS A MONOTHERAPY AND/OR STEM CELL ADJUVANT THERAPY FOR PULMONARY FIBROSIS | THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (US) | 2022-11-24 | — | — | US | disclosed |
| US-11386555-B2 | Assessment of arterial calcifications | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-07-12 | — | — | US | disclosed |
| CN-109796414-B | Method for continuously preparing rosuvastatin intermediate by adopting micro-channel modular reaction device | 中国药科大学 | 2022-05-20 | — | — | CN | disclosed |
| US-20070093527-A1 | Methods for treating disorders associated with hyperlipidemia in a mammal | AEGERION PHARMACEUTICALS, INC. | 2007-04-26 | — | — | US | disclosed |
| WO-2007047725-A2 | METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL | AEGERION PHARMACEUTICALS (US) | 2007-04-26 | — | — | WO | disclosed |
| CN-1898233-A | Process for producing rosuvastatin -7- [ 4- (4-fluorophenyl) -6-isopropyl-2- [ methyl (methylsulfonyl) amino ] pyrimidin-5-yl ] (3R, 5S) -3, 5-dihydroxyhept-6-enoic acid calcium salt and crystalline intermediate thereof | ASTRAZENECA UK LTD (GB) | 2007-01-17 | — | — | CN | disclosed |
| EP-1740164-A1 | STATINS FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA | Alcon Inc. (CH) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105069-A1 | STATINS FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA | ALCON, INC. (CH) | 2005-11-10 | — | — | WO | disclosed |
| CN-1660432-A | Preparation of compound Tatin class and hepatic protectant and applications | FUKANGREN BIOLOGICAL PHARMACEUTICAL SCIENCE & TECHNOLOGY CO LTD (CN) | 2005-08-31 | — | — | CN | disclosed |
| WO-2005040134-A1 | PROCESS FOR THE PREPARATION OF AMORPHOUS ROSUVASTATIN CALCIUM | RANBAXY LABORATORIES LIMITED (IN) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360086-A1 | ROSUVASTATIN CALCIUM AND PROCESS FOR PRODUCING INTERMEDIATE THEREOF | HMGCR, COASY, PCSK9 | HMGCR 1/4885ALDH1A1 2111/4885CYP3A4 163/4885 |
| US-12622895-B2 | Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases | HTR1D, PARK7, HTR3A | HMGCR 248/4885ALDH1A1 2384/4885CYP3A4 219/4885 |
| US-20070093527-A1 | Methods for treating disorders associated with hyperlipidemia in a mammal | HMGCR, MTTP, CETP | HMGCR 1/4885ALDH1A1 2532/4885CYP3A4 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.